As a factor commonly used in routine MRD measurement for ALL patients in our institute, the percentage of CD123 expression at initial diagnosis was easily accessible and could provide more information for risk assessment in pediatric B-ALL. This evidence concerns the gene IL3RA and acute lymphoblastic leukemia.